3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 1/2
10
Phase 1
6
Phase 3
3
Status
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
20
Thoracic
18
Genitourinary
14
Gastrointestinal
8
Other solid neoplasm
3
Head & Neck
3
CNS
2
Sarcoma
1
Gynecologic
1
Conditions
Mesothelioma
3
Mesothelioma, Malignant
2
Interventions
Carboplatin
10
Cisplatin
7
Pemetrexed
6
Vincristine
5
Nivolumab
5
Etoposide
4
Topotecan
3
Specimen Handling
3
Ipilimumab
3
Injections
3
Doxorubicin
3
Talc
2
Radiotherapy
2
Paclitaxel
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Filgrastim
2
Drug Therapy
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
sintilimab
1
ranpirnase
1
raltitrexed
1
pertuzumab
1
pembrolizumab
1
onartuzumab
1
iniparib
1
durvalumab
1
dostarlimab
1
crofelemer
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Ipilimumab
×
Other solid neoplasm
×
Clear all
NCT06097728
2026-04-28
eVOLVE-Meso
AstraZeneca
Phase 3
Recruiting
825 enrolled
NCT04334759
2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3
Completed
214 enrolled
NCT02899299
2024-05-21
CheckMate743
Bristol-Myers Squibb
Phase 3
Completed
605 enrolled
17 charts
1 FDA